Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits

Gwendalyn D. King, Kurt M. Kroeger, Catherine J. Bresee, Marianela Candolfi, Chunyan Liu, Charlene M. Manalo, A. K.M.Ghulam Muhammad, Robert N. Pechnick, Pedro R. Lowenstein, Maria G. Castro

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Glioblastoma multiforme (GBM) is an invasive and aggressive primary brain tumor which is associated with a dismal prognosis. We have earlier developed a macroscopic, intracranial, syngeneic GBM model, in which treatment with adenoviral vectors (Ads) expressing herpes simplex virus type 1 thymidine kinase (HSV1-TK) plus ganciclovir (GCV) resulted in survival of ∼20% of the animals. In this model, treatment with Ads expressing Fms-like tyrosine kinase 3 ligand (Flt3L), in combination with Ad-HSV1-TK improves the survival rate to ∼70% and induces systemic antitumor immunity. We hypothesized that the growth of a large intracranial tumor mass would cause behavioral abnormalities that can be reversed by the combined gene therapy. We assessed the behavior and neuropathology of tumor-bearing animals treated with the combined gene therapy, 3 days after treatment, in long-term survivors, and in a recurrent model of glioma. We demonstrate that the intracranial GBM induces behavioral deficits that are resolved after treatment with Ad-Flt3L/Ad-TK (+GCV). Neuropathological analysis of long-term survivors revealed an overall recovery of normal brain architecture. The lack of long-term behavioral deficits and limited neuropathological abnormalities demonstrate the efficacy and safety of the combined Ad-Flt3L/Ad-TK gene therapy for GBM. These findings can serve to underpin further developments of this therapeutic modality, leading toward implementation of a Phase I clinical trial.

Original languageEnglish (US)
Pages (from-to)682-690
Number of pages9
JournalMolecular Therapy
Volume16
Issue number4
DOIs
StatePublished - Apr 2008
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits'. Together they form a unique fingerprint.

Cite this